AI English summary of an SEC filing — figures as filed
Baxter International BAXThe company said net sales from its Kidney Care segment were $1.10 billion in Q1 2024, or about 31% of consolidated net sales. It said the separation is expected to be completed in the second half of 2024, regardless of the structure chosen. It added that separation-related costs were $92 million in Q1.
Key points
AI summaryThe company said net sales from its Kidney Care segment were $1.10 billion in Q1 2024, or about 31% of consolidated net sales. It said the separation is expected to be completed in the second half of 2024, regardless of the structure chosen. It added that separation-related costs were $92 million in Q1.
Baxter said net income attributable to Baxter stockholders was $37 million in Q1 2024, or $0.07 per diluted share, and that special items reduced net income by $294 million, or $0.58 per diluted share. Loss from continuing operations for Q1 2023 was $1 million.
The company said net sales in Q1 2024 rose 6% at Medical Products and Therapies, 11% at Pharmaceuticals and 3% at Kidney Care, and fell 9% at Healthcare Systems and Technologies. It cited the timing of capital orders from hospital customers as a factor in the latter decline.
The company said cash flows from operations from continuing operations were $163 million in Q1 2024, lower than $469 million in the prior year period. It said cash and cash equivalents were $3.03 billion as of March 31, 2024, and long-term debt and finance lease obligations were about $13.73 billion, with no short-term debt.
Key figures
Quarter ended March 31, 2024
- Revenue
- $3.6B
- Operating income
- $187M
- Net income
- $37M
- EPS
- $0.07
- Gross profit
- $1.4B
- Operating cash flow
- $163M
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Kidney Care Separation Plan and Separation Costs
The company said net sales from its Kidney Care segment were $1.10 billion in Q1 2024, or about 31% of consolidated net sales. It said the separation is expected to be completed in the second half of 2024, regardless of the structure chosen. It added that separation-related costs were $92 million in Q1.
Source · Based on the MD&A text of the filing
Net Income and Special Items Impact for Q1
Baxter said net income attributable to Baxter stockholders was $37 million in Q1 2024, or $0.07 per diluted share, and that special items reduced net income by $294 million, or $0.58 per diluted share. Loss from continuing operations for Q1 2023 was $1 million.
Source · Based on the MD&A text of the filing
Net Sales Changes by Segment
The company said net sales in Q1 2024 rose 6% at Medical Products and Therapies, 11% at Pharmaceuticals and 3% at Kidney Care, and fell 9% at Healthcare Systems and Technologies. It cited the timing of capital orders from hospital customers as a factor in the latter decline.
Source · Based on the MD&A text of the filing
Operating Cash Flow and Liquidity
The company said cash flows from operations from continuing operations were $163 million in Q1 2024, lower than $469 million in the prior year period. It said cash and cash equivalents were $3.03 billion as of March 31, 2024, and long-term debt and finance lease obligations were about $13.73 billion, with no short-term debt.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…